Earnings Feed
Start Free
Home/Filings/4/0001951869-25-000002
4//SEC Filing

Olivo Alicia C 4

Accession 0001951869-25-000002

CIK 0001077183other
View on SEC.govCompany Profile

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 4:38 PM ET

Size

27.1 KB

Accession

0001951869-25-000002

Insider Transaction Report

Form 4
Period: 2025-08-01
NEOGENOMICS INCNEO
Olivo Alicia C
EVP, GC & Business Development
Transactions
  • Tax Payment

    Common Stock

    2025-08-01−14→ 49,606 total
Holdings

  • Stock Option (Right to Buy)

    Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying)
    1,024

  • Performance Stock Unit

    Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying)
    19,508

  • Stock Option (Right to Buy)

    Exercise: $10.05Exp: 2029-09-01→ Common Stock (55,332 underlying)
    55,332

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (6,503 underlying)
    6,503

  • Stock Option (Right to Buy)

    Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying)
    516

  • Stock Option (Right to Buy)

    Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying)
    22,222

  • Stock Option (Right to Buy)

    Exercise: $13.05Exp: 2035-02-21→ Common Stock (107,450 underlying)
    107,450

  • Stock Option (Right to Buy)

    Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying)
    1,117

  • Stock Option (Right to Buy)

    Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying)
    36,508

  • Restricted Stock Unit

    Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
    59,382

  • Performance Stock Unit

    Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
    25,330

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (63,238 underlying)
    63,238

  • Stock Option (Right to Buy)

    Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying)
    1,046

  • Stock Option (Right to Buy)

    Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
    42,344

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (16,886 underlying)
    16,886
Footnotes (17)
  • [F1]Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2025 vesting of restricted stock.
  • [F10]Once vested, the shares of common stock are not subject to expiration.
  • [F11]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
  • [F12]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F13]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
  • [F14]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F15]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
  • [F16]On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F17]On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F2]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F3]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F4]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F5]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F6]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F7]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F8]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F9]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Documents

1 file

Issuer

NEOGENOMICS INC

CIK 0001077183

→
Entity typeother

Related Parties

1
  • filerCIK 0001951869

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 4:38 PM ET
Size
27.1 KB
View on SEC.gov